2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4706 Hydroxyurea reduces transfusions for children with sickle cell anemia in Uganda: Final results from the alternative dosing and prevention of transfusions (ADAPT) trial

Alexandra Power-Hays, MD, Ruth Namazzi, MMED2, Charles Kato, MBChB3, Andrea L Conroy, PhD4, Chandy C. John, MD5, Robert O. Opoka, MBChB, PhD6, Susan Stuber, MA7, Adam Lane, PhD8, Teresa Smith Latham, DrPH9, Russell E E. Ware, MD, PhD10
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Makere University School of Medicine, Kampala, Uganda
3 Global Health Uganda, Jinja, Uganda
4 Indiana University School of Medicine, Indianapolis, Indiana, United States
5 Indiana University School of Medicine, Indianapolis, Indiana, United States
6 Aga Khan University, Nairobi, Kenya
7 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
8 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
9 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
10 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Introduction: Without access to disease-modifying therapy, such as hydroxyurea, people living with sickle cell anemia (SCA) rely heavily on blood transfusions to treat acute, often life-threatening complications. Several studies suggest hydroxyurea reduces transfusion use for SCA complications, but this has not yet been evaluated as a primary outcome in a controlled clinical trial. The benefits of hydroxyurea are greatest at individual maximum tolerated dose (MTD), which varies between individuals due to pharmacokinetic (PK) differences. If feasible, upfront individualized PK-guided hydroxyurea dosing may increase the number of children started at an optimal dose, thereby maximizing safety and benefits.

Methods: Alternative Dosing And Prevention of Transfusions (ADAPT, NCT05662098) was a prospective, open-label trial to evaluate the impact of hydroxyurea on transfusion rates for children with SCA in Jinja, Uganda. The primary study endpoint was the transfusion incidence rate ratio (IRR) between a 3-month screening period and a 36-month treatment period, and we hypothesized a 50% reduction in the blood transfusion rate with hydroxyurea treatment compared with the pre-treatment period. Secondary aims included characterizing transfusion indications and determining the feasibility of PK-guided hydroxyurea dosing in this limited-resource setting. Children 1-10 years old with HbSS were included. All participants underwent first-dose PK testing with sparse sample collection, portable high performance liquid chromatography (HPLC, SmartLife) analysis, and PK-dose generation with web-based software (HdxSim). Participants for whom an individual PK dose between 15-35 mg/kg/day was generated started on their individual dose and the remainder started at a default dose (20 mg/kg/day) per national guidelines; both groups followed the same dose escalation protocol to reach MTD. The decision to transfuse was made by local clinicians based on national guidelines.

Results: ADAPT enrolled 106 children (50% female, 4.3 ± 2.3 years of age). Most (83, 78%) reported ≥1 transfusion prior to enrollment, and 37 (35%) reported ≥3 lifetime transfusions. During screening, the transfusion rate was 2.3 units per person-year with 62 units of blood administered in 27 person-years. On hydroxyurea treatment, the transfusion rate decreased 60% to 0.9 units per person-year (IRR 0.40, 95% CI 0.26-0.60, p<0.0001) with 289 units administered during 315 person-years. Throughout the trial, anemia was the primary transfusion indication followed by malaria with significant reductions in both during treatment (IRR 0.32, 95% CI 0.22-0.47, p<0.0001 for anemia and IRR 0.52,95% CI 0.33-0.87, p=0.01 for malaria). Transfusions for SCA-related complications (stroke, acute chest syndrome, splenic sequestration) decreased by 65% (IRR 0.35, 95% CI 0.15 to 0.95, p=0.03). An individualized PK dose was generated for 82 children (78%); these doses were typically within or slightly above the protocol-defined dosing range. Ultimately, 29 (28%) participants started on their individualized PK-guided dose (28.3 ± 5.3 mg/kg/day) and maintained that dose throughout the trial (Month 36 dose = 28.0 ± 2.7 mg/kg/day). In contrast, children who started on the default dose (20 mg/kg/day) escalated toward a similar dose (Month 36 = 27.0 ± 5.2 mg/kg/day). Those receiving the PK-guided dose had higher HbF at Month 12 than the default dose (34 ± 15% vs 28 ± 11%, p=0.02), a gap that closed by Month 36 after dose escalation. The transfusion rates during treatment for both dosing groups were similar.

Conclusion: ADAPT demonstrates that hydroxyurea treatment at MTD significantly reduces transfusion use by 60% in children with SCA in Uganda. Hydroxyurea is, therefore, an important individual and public health strategy to decrease transfusion use in Africa, where at least one-third of pediatric transfusions are administered to children with SCA. PK-guided doses were close to the individual MTD and had significantly higher HbF after one year of treatment than standard dose escalation. Regardless of the dosing approach, it is critical to expand access to hydroxyurea for SCA populations across Africa to reduce SCA complications and lower the transfusion rate in young children.

Alexandra Power-Hays, MD: No relevant conflicts of interest to declare.